Driehaus Capital Management Reduces $2M in Scholar Rock Holding Corporation ($SRRK)
Driehaus Capital Management reduced its position in Scholar Rock, trimming 32,644 shares.
Key Points
- Driehaus Capital Management trimmed its stake in Scholar Rock Holding Corporation by 32,644 shares, a 1.7% decrease, now holding 1,920,233 shares valued at $103.3 million.
- Shares of NasdaqGS:SRRK traded near $53.79 on Friday with a market cap of $6.45 billion and a forward P/E of -22.7.
- Analysts from Barclays, HC Wainwright & Co., and others maintain a 'buy' rating on Scholar Rock with price targets ranging from $50 to $70.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Driehaus Capital Management has trimmed its stake in Scholar Rock Holding Corporation (NasdaqGS:SRRK), reducing its holdings by 32,644 shares. This represents a 1.7% decrease, leaving Driehaus with 1,920,233 shares valued at approximately $103.3 million as of the latest Form 13F filing with the SEC for the period ending May 15, 2026.
Driehaus Capital Management vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Driehaus Capital Management's Scholar Rock Holding Corporation Position
Driehaus Capital Management reduced its holdings in Scholar Rock by 32,644 shares, decreasing its position by 1.7%. The firm now holds 1,920,233 shares valued at about $103.3 million. Previously, Driehaus held 1,952,877 shares.
Other Institutional Activity in Scholar Rock Holding Corporation
FMR LLC increased its holdings in Scholar Rock by 1,862,477 shares, ending with 17,243,152 shares worth about $847.7 million, marking a 12.1% increase. REDMILE GROUP, LLC significantly boosted its position by 3,845,775 shares to 9,066,621 shares, a 73.7% increase, valued at $445.7 million. BLACKROCK, INC. also increased its stake by 252,259 shares to a total of 7,469,293 shares, valued at approximately $367.2 million, marking a 3.5% rise. Meanwhile, SIREN, L.L.C. and SAMSARA BIOCAPITAL, LLC maintained their positions without change.
Scholar Rock Holding Corporation Stock Down 4.8%
Shares of NasdaqGS:SRRK traded near $53.79 on Friday. Scholar Rock has a market capitalization of approximately $6.45 billion and a forward P/E ratio of -22.7, indicating it is not currently profitable. The stock's 52-week range is between $27.07 and $53.86. It has a 50-day moving average of $47.68 and a 200-day moving average of $42.50. The company's beta is 0.695, suggesting lower volatility than the market. Scholar Rock also maintains a strong liquidity position with a current ratio of 8.639 and a quick ratio of 8.407.
$SRRK stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Scholar Rock reported earnings with a negative EPS of -3.45, reflecting ongoing investments in its development pipeline. The company is not currently profitable, with a return on equity of -1.39. The next earnings report is expected on May 7, 2026.
Insider Buying and Selling at Scholar Rock Holding Corporation
Several insiders, including Gilman Michael, Flier Jeffrey, Burow Kristina, Peng Katie, and Reed Joshua, purchased shares on June 4, 2026. Each insider bought between 4,310 and 6,839 shares, though the transaction price was not disclosed. These purchases were not made under any pre-arranged trading plan.
Analysts Set New Price Targets
On May 8, 2026, Barclays maintained its 'buy' rating on Scholar Rock with a price target of $55. Similarly, HC Wainwright & Co. kept a 'buy' rating with a $65 target. Canaccord Genuity initiated coverage on April 21, 2026, with a 'buy' rating and a $62 target. The consensus among 16 analysts is a 'strong buy' with an average target price of $59.31.
About Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical company based in Cambridge, Massachusetts, focusing on developing treatments for rare neuromuscular diseases like spinal muscular atrophy (SMA). Under the leadership of CEO David L. Hallal, the company employs 289 people. Scholar Rock's proprietary platform targets the activation of growth factors, with key products in clinical trials aimed at conditions such as SMA and muscular dystrophies.
Bottom Line
Driehaus Capital Management's slight reduction in its Scholar Rock stake highlights ongoing interest in the biopharmaceutical company. Investors keep a close watch on these filings for insights into institutional strategies, although they reflect past decisions and not necessarily current positions. Scholar Rock's stock remains attractive to analysts, who see potential in its innovative approach to treating severe neuromuscular diseases.
Get Scholar Rock Holding Corporation alerts
New 13F filings, insider trades, and analyst moves on $SRRK, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.